Emily Field
Stock Analyst at Barclays
(0.93)
# 3,856
Out of 5,182 analysts
15
Total ratings
25%
Success rate
-4.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $26.48 | -5.59% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $110.03 | +27.24% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $129.26 | +19.91% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $874.00 | +54.46% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $58.26 | +28.73% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $183.38 | +0.88% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $339.57 | +3.07% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $197.69 | +39.11% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $41.17 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $28.43 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $54.47 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $775.03 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.48
Upside: -5.59%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $110.03
Upside: +27.24%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $129.26
Upside: +19.91%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $874.00
Upside: +54.46%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $58.26
Upside: +28.73%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $183.38
Upside: +0.88%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $339.57
Upside: +3.07%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $197.69
Upside: +39.11%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $41.17
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $28.43
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $54.47
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $775.03
Upside: -